Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnSanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big Share XSanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnhttps://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/
IL-6 drugs do work in COVID-19, says UK, as it plans NHS useNew data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus Share XIL-6 drugs do work in COVID-19, says UK, as it plans NHS usehttps://pharmaphorum.com/news/il-6-drugs-covid-19-new-trial/
The top 5 pharma M&A deals of 20202020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout Share XThe top 5 pharma M&A deals of 2020https://pharmaphorum.com/views-and-analysis/the-top-5-pharma-ma-deals-of-2020/
EUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedUK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 Share XEUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedhttps://pharmaphorum.com/news/eusa-pharma-hopes-il-6-drug-will-work-in-covid-19-where-class-rivals-failed/
Deep Dive: Patients and PartnershipsAs this issue’s title suggests, patient centricity is about more than just talking points and marketing strategies – Share XDeep Dive: Patients and Partnershipshttps://pharmaphorum.com/views-analysis-patients/deep-dive-patients-and-partnerships/
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
FDA to expedite development of two Sanofi rare disease drugsThe FDA has agreed to expedite development of two rare disease drugs from Sanofi. The most significant of Share XFDA to expedite development of two Sanofi rare disease drugshttps://pharmaphorum.com/news/fda-to-expedite-development-of-two-sanofi-rare-disease/
Fresh doubts over BMS’ merger payout as FDA delays key drug reviewHolders of a risky “bet” on three Bristol-Myers Squibb drugs are looking increasingly unlikely to get their pay-out Share XFresh doubts over BMS’ merger payout as FDA delays key drug reviewhttps://pharmaphorum.com/news/fresh-doubts-over-bms-merger-payout-as-fda-delays-key-drug-review/
NICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drugPreviously-untreated patients with hepatocellular carcinoma (HCC), a common form of liver cancer, will have an immunotherapy-based treatment option Share XNICE okays Roche liver cancer immunotherapy, Sanofi’s rare disease drughttps://pharmaphorum.com/news/nice-okays-roche-liver-cancer-immunotherapy-sanofis-rare-disease-drug/
